Table 1.
Baseline Characteristics of the Patients With Pulmonary LCNEC
| Characteristics | Total (n = 51) | Nivolumab (n = 17) | Conventional Treatment (n = 34) | p Value |
|---|---|---|---|---|
| Age, y, median (range) | 59 (38–82) | 59 (42–79) | 59 (38–82) | 0.8155 |
| Sex, male, n (%) | 41 (80) | 12 (71) | 29 (85) | 0.2700 |
| Smoking status, n (%) | 49 (2)a | 17 (0)a | 32 (2)a | 1.0000 |
| Current/former smoker | 48 (98) | 17 (100) | 31 (97) | |
| ECOG PS, n (%) | 43 (8)a | 12 (5)a | 31 (3)a | 0.1630 |
| >1 | 7 (16%) | 0 (0%) | 7 (23%) | |
| Weight loss, n (%) | 44 (7)a | 13 (4)a | 31 (3)a | 1.0000 |
| >10% | 12 (27) | 3 (23) | 9 (29) | |
| Stage, n (%) | ||||
| III | 4 (8) | 1 (6) | 3 (9) | 1.0000 |
| IV | 47 (92) | 16 (94) | 31 (91) | |
| De novo, n (%) | 43 (84) | 13 (77) | 30 (88) | 0.4156 |
| Recurrent, n (%) | 8 (16) | 4 (24) | 4 (12) | |
| Number of metastatic organs, n (%) | ||||
| <3 | 40 (79) | 16 (94) | 24 (71) | 0.0751 |
| ≥3 | 11 (22) | 1 (6) | 10 (29) | |
| Brain metastasis, n (%) | 10 (20) | 2 (12) | 8 (24) | 0.4632 |
| Number of courses, median (range) | 2 (1–6) | 3 (2–6) | 1 (1–4) | <0.0001 |
ECOG, Eastern Cooperative Oncology Group; LCNEC, large-cell neuroendocrine cancer of the lung; PS, performance status.
a
Missing date.